The Unlimited Energy Stack: Mitochondria, GH & Repair
Five research peptides layered around one idea — make more cellular energy and recover faster from using it. SS-31 and MOTS-c target the mitochondria directly; CJC-1295/Ipamorelin drives the GH/IGF-1 recovery axis; BPC-157 and TB-500 handle systemic and soft-tissue repair.
What's in the Stack
SS-31 (elamipretide) concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, the lipid that organizes the electron-transport chain. Protecting cardiolipin preserves ATP throughput and cuts electron leak. It is the most-studied mitochondria-targeted peptide, with Phase 2 human data in HFpEF (STARLITE, EVOLUTION-HF). Research dosing is ~5–10 mg/day subcutaneous — it is not orally bioavailable.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that activates AMPK — the same energy-sensor exercise triggers — and is associated with PGC-1α-driven metabolic reprogramming. In humans, muscle MOTS-c rises ~11.9× after a single bout of exercise (Reynolds 2021); in aged mice it roughly doubled treadmill capacity. Almost entirely preclinical. Typical research dose ~10 mg.
A GHRH analog (CJC-1295) plus a selective GHRP (Ipamorelin) amplifies the natural overnight GH pulse, feeding the IGF-1 recovery and deeper-sleep arm of the stack. In Teichman 2006 (n=57) a single CJC-1295 DAC dose kept GH elevated 6+ days and IGF-1 elevated 9–11 days. Ipamorelin is uniquely selective — no cortisol/prolactin spike (Raun 1998).
BPC-157, a pentadecapeptide from gastric juice, modulates the VEGFR2 / nitric-oxide (Akt-eNOS) angiogenesis pathway and reduces inflammatory signaling — supporting gut, vascular, and connective-tissue repair and raising training tolerance. 544+ studies, overwhelmingly preclinical; human data is three small pilots plus an IV pharmacokinetic study. Reported research dose 200–500 mcg/day.
TB-500, a synthetic fragment of thymosin beta-4, sequesters G-actin to drive cell migration and angiogenesis in damaged tissue — the systemic complement to BPC-157’s more local repair. Tendon and wound data come from rats and mice (Philp 2007; Bock-Marquette 2004 showed ~50% MI scar reduction). The only human Tβ4 trial was eye drops (Sosne 2014). The BPC-157 + TB-500 pairing is popular but has zero human RCTs.
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- Two of the five peptides have human trial data: SS-31/elamipretide reached Phase 2 in HFpEF (STARLITE, EVOLUTION-HF), and CJC-1295 DAC has a published n=57 human pharmacokinetic study (Teichman 2006, PMID 16882835).
- MOTS-c is exercise-induced: human muscle MOTS-c rises ~11.9× after a single bout of exercise (Reynolds, Nature Communications 2021, PMID 33547290), and it activates AMPK, the same energy sensor exercise triggers.
- A single CJC-1295 DAC injection elevated GH for 6+ days and IGF-1 for 9–11 days, and Ipamorelin is the most selective GHRP — robust GH release without raising cortisol or prolactin (Raun 1998, PMID 9849822).
- BPC-157 acts through the VEGFR2 / nitric-oxide angiogenesis pathway; an IV pharmacokinetic study in two healthy adults (doses up to 20 mg) reported no adverse events and clearance within 24 hours.
- TB-500 (thymosin beta-4 fragment) drives cell migration via actin sequestration; Bock-Marquette 2004 (PMID 15472116) showed ~50% scar reduction in a mouse MI model, and Philp 2007 (PMID 17404022) showed dermal wound repair.
- The two recovery peptides target different layers: BPC-157 leans systemic/gut/vascular and local, while TB-500 leans whole-body soft-tissue migration — the rationale behind pairing them.
- No human trial has ever tested these five peptides together as a stack. Every claimed synergy is theoretical, not measured.
- Three of the five — MOTS-c, BPC-157, and TB-500 — rest almost entirely on animal and in-vitro data. Rodent results do not reliably predict human outcomes.
- None of these peptides is FDA approved for energy, performance, or recovery. SS-31 development (elamipretide) stalled at the Phase 2/3 boundary; the only human Tβ4 trial was eye drops (Sosne 2014, PMID 25325753).
- Long-term safety of chronic GH/IGF-1 stimulation is unsettled — chronically elevated IGF-1 carries a theoretical oncology concern, so IGF-1 monitoring is essential on the CJC-1295/Ipamorelin arm.
- There is no validated combined dosing schedule. The cadences here are extrapolated from each compound’s individual research-use reports, not from a trial of the stack.
- Quality and purity of research peptides vary widely between sources; nothing here is a recommendation to obtain or self-administer any of these compounds.
Frequently Asked Questions
What is the Unlimited Energy Stack?
It is a research-oriented combination of five peptides organized around cellular energy and recovery: SS-31 and MOTS-c target the mitochondria, CJC-1295 with Ipamorelin drives the GH/IGF-1 recovery and sleep axis, and BPC-157 with TB-500 handle systemic and soft-tissue repair. It is a conceptual framework drawn from the individual compounds — not an FDA-approved or clinically validated protocol.
Which peptides in the stack actually have human data?
Two. SS-31 (elamipretide) reached Phase 2 human trials for heart failure (STARLITE and EVOLUTION-HF). CJC-1295 DAC has a published human pharmacokinetic study in 57 healthy adults (Teichman 2006). MOTS-c, BPC-157, and TB-500 rely overwhelmingly on animal and in-vitro research, with only small human pilots for BPC-157 and TB-500.
How do SS-31 and MOTS-c support energy differently?
SS-31 protects cardiolipin in the inner mitochondrial membrane, helping preserve ATP throughput and reduce electron leak. MOTS-c is a mitochondrial-derived peptide that activates AMPK and acts as an exercise mimetic — in humans, muscle MOTS-c rises about 11.9-fold after a single bout of exercise. One protects the energy machinery; the other signals it to run like a workout.
Why include CJC-1295 and Ipamorelin in an energy stack?
Energy is as much about recovery as production. CJC-1295 (a GHRH analog) plus Ipamorelin (a selective GHRP) amplifies the natural overnight growth-hormone pulse, supporting deeper sleep and IGF-1-driven tissue recovery. In Teichman 2006, one CJC-1295 DAC dose kept GH elevated 6+ days and IGF-1 elevated 9–11 days, and Ipamorelin does this without raising cortisol or prolactin (Raun 1998).
Why are BPC-157 and TB-500 paired?
They are thought to address repair at different scales: BPC-157 modulates angiogenesis through the VEGFR2 / nitric-oxide pathway and is associated with gut, vascular, and local connective-tissue repair, while TB-500 (a thymosin beta-4 fragment) promotes whole-body cell migration via actin sequestration. The pairing is popular in the research community, but no human randomized trial has tested the combination.
Is this stack proven or safe?
No combined human trial of these five peptides exists, and none is FDA approved for energy or recovery. Three of the five are almost entirely preclinical. Chronic GH/IGF-1 stimulation carries a theoretical oncology concern, making IGF-1 monitoring important on the CJC-1295/Ipamorelin arm. This page is educational only and not a recommendation to use any of these compounds.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
None of the five peptides in this stack is FDA approved for energy, performance, or recovery, and no human trial has tested the combination. SS-31, MOTS-c, CJC-1295, Ipamorelin, BPC-157, and TB-500 are research compounds. Nothing here is a recommendation to obtain or self-administer them.
Figures are cited from peer-reviewed sources reused from our individual compound pages: Reynolds et al., Nature Communications 2021 (PMID 33547290); Lee et al., Cell Metabolism 2015 (PMID 25738459); Teichman et al., JCEM 2006 (PMID 16882835); Raun et al., Eur J Endocrinol 1998 (PMID 9849822); Bock-Marquette et al. 2004 (PMID 15472116); Philp et al. 2007 (PMID 17404022); Sosne et al. 2014 (PMID 25325753). Consult a qualified healthcare provider before any intervention.